Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal midazolam for palliation of dyspnoea in life-limiting disease
ACTRN12609000506291Phase 3Terminated
- Sponsor
- Arohanui Hospice
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial comparing Intranasal midazolam with Placebo nasal spray (2 arms). Primary endpoint: Primary: dyspnoea intensity difference at 15 minutes. Started Dec 2009; status: terminated.
02
Drugs
midazolam
Beyond the preview
Go deeper on ACTRN12609000506291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000506291.